These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
558 related articles for article (PubMed ID: 34987518)
1. The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer. van Dijk N; Gil-Jimenez A; Silina K; van Montfoort ML; Einerhand S; Jonkman L; Voskuilen CS; Peters D; Sanders J; Lubeck Y; Broeks A; Hooijberg E; Vis DJ; van den Broek M; Wessels LFA; van Rhijn BWG; van der Heijden MS Front Immunol; 2021; 12():793964. PubMed ID: 34987518 [TBL] [Abstract][Full Text] [Related]
2. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13 Hu C; You W; Kong D; Huang Y; Lu J; Zhao M; Jin Y; Peng R; Hua D; Kuang DM; Chen Y Gastroenterology; 2024 Jun; 166(6):1069-1084. PubMed ID: 38445519 [TBL] [Abstract][Full Text] [Related]
3. Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma. Vanguri RS; Smithy JW; Li Y; Zhuang M; Maher CA; Aleynick N; Peng X; Al-Ahmadie H; Funt SA; Rosenberg JE; Iyer G; Bajorin D; Mathews JC; Nadeem S; Panageas KS; Shen R; Callahan MK; Hollmann TJ J Pathol; 2023 Nov; 261(3):349-360. PubMed ID: 37667855 [TBL] [Abstract][Full Text] [Related]
4. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. van Dijk N; Gil-Jimenez A; Silina K; Hendricksen K; Smit LA; de Feijter JM; van Montfoort ML; van Rooijen C; Peters D; Broeks A; van der Poel HG; Bruining A; Lubeck Y; Sikorska K; Boellaard TN; Kvistborg P; Vis DJ; Hooijberg E; Schumacher TN; van den Broek M; Wessels LFA; Blank CU; van Rhijn BW; van der Heijden MS Nat Med; 2020 Dec; 26(12):1839-1844. PubMed ID: 33046870 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Goc J; Germain C; Vo-Bourgais TK; Lupo A; Klein C; Knockaert S; de Chaisemartin L; Ouakrim H; Becht E; Alifano M; Validire P; Remark R; Hammond SA; Cremer I; Damotte D; Fridman WH; Sautès-Fridman C; Dieu-Nosjean MC Cancer Res; 2014 Feb; 74(3):705-15. PubMed ID: 24366885 [TBL] [Abstract][Full Text] [Related]
6. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125 [TBL] [Abstract][Full Text] [Related]
7. Spatial tertiary lymphoid structures imply response to anti-PD-1 plus anlotinib in advanced non-small cell lung cancer. Ma J; Deng Y; Zhang M; Zhang Q Immunology; 2024 Nov; 173(3):536-551. PubMed ID: 39078223 [TBL] [Abstract][Full Text] [Related]
8. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts. Bortolomeazzi M; Keddar MR; Montorsi L; Acha-Sagredo A; Benedetti L; Temelkovski D; Choi S; Petrov N; Todd K; Wai P; Kohl J; Denner T; Nye E; Goldstone R; Ward S; Wilson GA; Al Bakir M; Swanton C; John S; Miles J; Larijani B; Kunene V; Fontana E; Arkenau HT; Parker PJ; Rodriguez-Justo M; Shiu KK; Spencer J; Ciccarelli FD Gastroenterology; 2021 Oct; 161(4):1179-1193. PubMed ID: 34197832 [TBL] [Abstract][Full Text] [Related]
9. Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma. Zhao X; Yue D; Qian J; Zhang L; Song J; Zhang B; Zhang C; Sun L; Ma Y; Zhang H; Wang C Front Immunol; 2022; 13():794217. PubMed ID: 35173719 [TBL] [Abstract][Full Text] [Related]
10. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer. Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485 [TBL] [Abstract][Full Text] [Related]
11. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Lu Y; Ng AHC; Chow FE; Everson RG; Helmink BA; Tetzlaff MT; Thakur R; Wargo JA; Cloughesy TF; Prins RM; Heath JR Nat Commun; 2021 Jun; 12(1):4031. PubMed ID: 34188042 [TBL] [Abstract][Full Text] [Related]
12. Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy. Langouo Fontsa M; Padonou F; Willard-Gallo K Expert Rev Clin Immunol; 2024 Aug; 20(8):839-847. PubMed ID: 39007892 [TBL] [Abstract][Full Text] [Related]
14. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. Prakadan SM; Alvarez-Breckenridge CA; Markson SC; Kim AE; Klein RH; Nayyar N; Navia AW; Kuter BM; Kolb KE; Bihun I; Mora JL; Bertalan MS; Shaw B; White M; Kaplan A; Stocking JH; Wadsworth MH; Lee EQ; Chukwueke U; Wang N; Subramanian M; Rotem D; Cahill DP; Adalsteinsson VA; Miller JW; Sullivan RJ; Carter SL; Brastianos PK; Shalek AK Nat Commun; 2021 Oct; 12(1):5955. PubMed ID: 34642316 [TBL] [Abstract][Full Text] [Related]
15. Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response. Sadeghirad H; Monkman J; Tan CW; Liu N; Yunis J; Donovan ML; Moradi A; Jhaveri N; Perry C; Adams MN; O'Byrne K; Warkiani ME; Ladwa R; Hughes BGM; Kulasinghe A J Transl Med; 2024 Jul; 22(1):677. PubMed ID: 39049036 [TBL] [Abstract][Full Text] [Related]
16. Identification of Tertiary Lymphoid Structure-Associated Follicular Helper T Cells in Human Tumors and Tissues. Couillault C; Germain C; Dubois B; Kaplon H Methods Mol Biol; 2018; 1845():205-222. PubMed ID: 30141015 [TBL] [Abstract][Full Text] [Related]
17. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010 [TBL] [Abstract][Full Text] [Related]
18. Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer. Hummelink K; van der Noort V; Muller M; Schouten RD; van den Heuvel MM; Thommen DS; Smit EF; Meijer GA; Monkhorst K PLoS One; 2024; 19(7):e0293707. PubMed ID: 39083541 [TBL] [Abstract][Full Text] [Related]
19. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281 [TBL] [Abstract][Full Text] [Related]